E

Can AstraZeneca leapfrog the competition in lung cancer AGAIN?

Durvalumab grabs pole position in unresectable NSCLC amongst IO compounds

May 12, 2017
E

On Gritstone and neoantigens

A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?

May 4, 2017
E

AACR 2017 Preview 3

Washington Monument After exploring a mechanistic approach and a tumour type as part of our AACR annual…

March 8, 2017
E

Novel Way to Improve Checkpoint Inhibitor Efficacy

A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.

March 1, 2017
E

A completely novel approach to targeting hematologic malignancies

A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.

February 15, 2017
E

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017
E

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017
E

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017
E
View of Cambridge and Charles River

Does Neon Therapeutics lead the Neoantigen field?

Update on Neon Tx as they move into commercial new product development with their neoantigen platform.

January 13, 2017
E

The future of our cancer research business

A look at the emerging trends we can expect in 2017 for cancer research

January 3, 2017
E

How the Leukemia Lymphoma Society plans to Beat AML

Tackling heterogeneity in older people with AML using novel targeted therapies.

December 21, 2016
E
Downtown San Diego during ASH 2016

7 Things I Learned at #ASH16

Highlights (Part 1) from 2016 ASH Annual Meeting in San Diego - 7 initial impressions

December 6, 2016
E

Making breast cancer cells become normal again

Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?

November 30, 2016
E

ASH16 Abstracts are out! So What’s Hot at ASH16? My Initial Impressions

Initial impressions of abstracts for ASH16 in San Diego

November 3, 2016
E

Glycomics The Third Language of Life

How will glycomics impact cancer research? Some interesting new developments are emerging in this field

October 27, 2016
E

How do you calculate Immunoscore? A tour of HalioDx

Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay

October 3, 2016
E

François Romagné Accelerates Cancer Immunotherapy Innovation in Marseille

Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.

September 21, 2016
E

HalioDX CEO Vincent Fert outlines commercial strategy for Immunoscore in US and Europe

Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.

September 14, 2016
E

Modelling the Tumour Microenvironment

Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer

August 22, 2016
E

PsiOxus is a cancer immunotherapy company to watch – Part 2 of an interview with CEO John Beadle

Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.

August 17, 2016
E

Can PsiOxus become a world leading immuno-oncolytic virus company?

An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours

August 16, 2016
E

Biotech Mailbag – Jounce & the CAR T Race to Market

July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...

July 27, 2016
E

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E

5 Important and Emerging Trends from ASCO 2016

A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?

June 9, 2016
E

Drug Discovery Targets Cancer Vulnerabilities

Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.

May 20, 2016
E

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016
E

Can ADCs be adapted to tackling MRSA?

Can we use technological approaches from oncology to applying creative ways to treating bacterial infections?

April 27, 2016
E

Targeting Acquired Resistance in Prostate Cancer

The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.

April 4, 2016
E

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015
E

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015
E

Is ocrelizumab a game changer in MS?

At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.

October 11, 2015
E

Novel Targets Podcast 6 – Immune Agonists

What happens when we literally step on the gas with immune agonists?

September 24, 2015
E

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015
E

Biotech Strategy questions answered on neratinib, bavituximab, enzalutamide and more!

Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...

June 17, 2015
E
View of Cambridge and Charles River

Yumanity hopes to impact humanity – an interview with Dr Susan Lindquist

Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.

January 21, 2015
E

How Syros are changing biotech R&D

Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?

January 15, 2015
E

bluebird bio CEO Nick Leschly seeks to make hope a reality

Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.

January 14, 2015
E

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging

January 12, 2015
E

Biotech Strategy Blog – the year of the paywall

Thank you to all our subscribers for a great year!

September 17, 2014
E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E

Healthcare Innovation in Action: Designing for Dementia

Can design make a difference to those with dementia? Liverpool City Council's award-winning Sedgemoor Dementia Support Centre shows how design innovation can stimulate memories and offer improved quality of life.

April 28, 2014
E

Everton FC leads the way in community dementia support

Everton FC and Mersey Care NHS Trust use football memorabilia and activities at Goodison Park to stimulate memories and support members of the local community with dementia.

April 23, 2014
E

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
E

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E

2012 was a Grand Cru year for the FDA with 39 NMEs approved

FDA approved 39 new molecular entities in 2012. This is the highest number in the last 10 years. However, approval rate is not a surrogate benchmark for the state of innovation given that it can take several years to bring a new drug or biologic to market.

January 2, 2013
E

Innovation in Action: helping people to see again

FDA approves first artificial retina prosthesis, the Argus II from Second Sight. This is not a bionic eye. To date, only crude images can be detected. There is no dramatic restoration of sight or vision, instead retinal prostheses currently only offer the ability to detect light and large shapes. Several companies and research groups including Bionic Vision Australia are working on innovative retinal prostheses that aim to restore some vision.

September 17, 2012
E

Creating an artificial jellyfish to model the human heart

Creation of an artificial jellyfish advances the potential to reverse engineer the human heart

August 20, 2012
E

The Potential of Gene Therapy to Restore Hearing Loss

Restoration of hearing in mice by gene transfer is a major breakthrough

August 14, 2012
E
Science Translational Medicine Cover May 16

Repetitive brain injury from high impact sports generates similar pathophysiology to traumatic brain injury in soldiers blown up by IEDs

Several retired American Football stars have ended up with chronic traumatic encephalophy (CTE). It’s similar to Alzheimer’s disease in that the brain ends up with neurofibrillary tangles. CTE has also been seen in soldiers who have experienced blast induced traumatic brain injury (bTBI) from improvised explosive devices (IEDs)

May 21, 2012
E
Drug Development Pipeline

TEDMED 2012: Francis Collins on how to brings drugs to market faster

It can take 14 years of research and the screening of 10,000 compounds to bring 1 new drug to market.

May 18, 2012
E
Participant S3 drinking froma bottle using the DLR robotic arm

Innovation in Neurotechnology: how a paralyzed person uses thoughts to control a robotic arm

A tetraplegic (all four limbs paralyzed) is able to use her mind to control a robotic arm, 15 years after she became completely paralyzed & unable to speak.

May 16, 2012
E

A personal perspective on Alzheimer’s: my mother doesn’t dance anymore

I have a personal interest in Alzheimer’s disease. It’s an area where innovation needs to catch up with demand for treatment and therapies, not to treat it when it’s happened – it’s too late to untangle the damage, but to delay it’s occurrence in those at risk.

March 9, 2012
E

Implanted Wireless Microchip offers Osteoporosis Drug Delivery that improves patient Quality of Life

Robert Farra of MicroCHIPS, Inc. and research collaborators, describe a first-in-human testing of a wirelessly controlled drug delivery microchip.

February 20, 2012
E
Children's Hospital Boston Innovation Acceleration Program

Today is Innovation Day at Childrens Hospital Boston #iDay

Children’s Hospital Boston has an Innovation Acceleration Program focused on supporting “clinical care that impacts patients around the world.”

February 14, 2012
E

Blocking Sema4D may be a new osteoporosis target

Research published in the November 2011 issue of the journal Nature Medicine has highlighted a new potential target for osteoporosis drug development that acts on osteoblasts and promotes bone formation.

November 10, 2011
E

Discovering the cause of Lou Gehrig’s disease

Scientists from Northwestern University in Chicago report findings that could help develop drugs for patients with Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s disease.

August 31, 2011
E

Can we halt memory loss as we get older?

New research offers the hope that in the future we may be able to reverse or slow-down the age-related memory loss and cognitive defects we would otherwise experience.

August 26, 2011
E

Innovation – should companies take bigger risks and outsource pharma R&D?

"Rather than do research in house, companies should close their labs and outsource the work to tiny, nimble startups that can explore bigger, crazier ideas.”

August 3, 2011
E

How we may be able to rebuild The Six Million Dollar Man

The Six Million Dollar Man was fiction, but it is becoming closer to reality as a result of new research into how artificial limbs can integrate with human tissues

July 11, 2011
E

How does sunburn cause pain?

Research by John Dawes and colleagues at King’s College London & University College London has shed new light on how sunburn causes pain.

July 8, 2011
E

Regenerative Medicine: Tissue Engineered Airway Transplant

Researchers from University College London led by Prof. Alexander Seifalian designed and built a polymer based nanocomposite tracheal scaffold, which was then seeded with the patient’s own stem cells.

July 7, 2011
E

Science Translational Medicine on Innovation – part 1

With an image of Rodin’s bronze “The Thinker” on its cover suggesting deep thought and insight, the journal "Science Translational Medicine" analyzes the state of innovation.

July 7, 2011
E

Will the future offer artificial retina transplants?

A Nature article shows, for the first time, the ability to generate a three-dimensional culture of neural retinal tissue from mouse embryonic stem (ES) cells.

April 29, 2011
E

The future of Parkinson’s disease, part 2 of an interview with Dr Todd Sherer, Chief Program Officer, Michael J Fox Foundation

"The understanding of the genetics of Parkinson’s will certainly form the building blocks of some future breakthroughs. Now that we have very tangible therapeutic targets that we know can cause Parkinson’s, it makes a much more rational directed drug development program."

April 8, 2011
E

Making a difference to Parkinson’s Disease Research, an interview with Dr Todd Sherer, Michael J Fox Foundation

"The goal of the foundation, the goal of all the research that we are supporting is to develop new therapies for Parkinson’s disease patients."

March 31, 2011
E

Of Mice and Men

The March 17, 2011 edition of Nature, highlights how innovative preclinical animal models are having an impact on drug development.

March 25, 2011
E

Technology Innovation – the challenges and opportunities with robotic surgery

At the European Association of Urology (EAU) annual congress in Vienna, Associate Professsor Axel Merseburger from Hannover in Germany discussed some of the challenges with robotic surgery for prostatectomy or partial nepthrectomy.

March 19, 2011
E

Argus III is the next generation of artificial retina from Lawrence Livermore National Laboratory

Lawrence Livermore National Laboratory (LLNL) have produced an excellent video about their manufacturing of the Argus™ III artificial retina.

March 14, 2011
E

Artificial Retina Project shows power of collaboration to bring new products to market

The Artificial Retina Project is a case study on the success of collaboration.

March 14, 2011
E

New artificial retina restores some visual perception and improves autonomy

Detecting a door or a window may not be a big deal for all of us with normal vision, but for those who lose their sight, e.g. through retinitis pigmentosa (RP), a new "artificial retina" now provides hope of a better quality of life.

March 8, 2011
E

Targeting Sclerostin in Osteoporosis

Sclerostin is a protein produced by osteocytes within bone that inhibits bone formation. It is thought to pass through the surface of bone where it acts on osteoblasts (cells responsible for bone formation). There it binds to low-density lipoprotein receptors and inhibits the Wnt/beta-catenin signaling involved in bone mass regulation. Promising phase 2 trial data for a novel sclerostin inhibitor, romosozumab (AMG 785), in osteoporosis has just been published in the New England Journal of Medicine.

March 10, 2011
E

Merck’s cathepsin-K inhibitor odanacatib in osteoporosis

Cathepsin-K inhibition is a novel approach to osteoporosis treatment and Merck's odanacatib is leading the way in this new class of drugs.

February 11, 2011
E

Emerging drugs in development for Osteoporosis

The market opportunity for osteoporosis remains significant, affecting 44 million people in the United States over the age of 50, resulting in healthcare costs in excess of $15 billion a year.

February 8, 2011
E

New research points to role of Cystic Fibrosis Transmembrane Conductance Regulator Signaling in Emphysema

Developing drugs that target cystic fibrosis transmembrane regulator (CFTR) protein and mediate ceramide may have an important role to play in the treatment of emphysema

January 10, 2011